Clinical trials
Growth clinical trials
Below are recruiting growth clinical trials, each written for real people, not researchers. We’re tracking 295 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05423665Recruiting
Ultrasound check to spot early growth problems in twin pregnancies
This study uses a special ultrasound method (speckle tracking echocardiography) to look for early signs that a twin pregnancy may have impaired fetal growth. It may help clinicians detect problems earlier and better understand how twin babies’ hearts and growth are affected.
GhentAges 18–45 - NCT05099172RecruitingPhase 1/Phase 2
Targeted therapy for advanced lung cancer with EGFR or HER2 changes
This trial tests a new targeted drug for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2). The drug may slow cancer growth and help you live longer.
Gilbert, ArizonaAges 18 years+ - NCT04762992Enrolling by invitationPhase 3
Heparin medicine for early slow fetal growth in one pregnancy
This study tests whether a blood-thinner medicine (LMWH) can improve outcomes for people carrying a singleton baby with early signs of slow growth. It compares LMWH against standard care to see if treatment helps the baby and pregnancy stay safer.
LisbonAges 18 years+ - NCT04294368Recruiting
Fortifying donor breast milk for very premature babies
This study tests whether adding extra nutrition (fortifying) to donated breast milk helps very premature infants grow better and safely. You might be offered a fortified donor milk feeding plan if your baby meets the timing and medical criteria.
New York, New YorkAges 1 day–3 weeks - NCT03501589Enrolling by invitation
Medicine aims to help regrowing growth cartilage
This trial is testing a treatment intended to affect the growth plate—the cartilage area that helps bones grow—in people who still are growing. It looks at whether changing signals in the growth plate can improve healing or regrowth after surgery removes part of that area as part of routine care.
Rochester, MinnesotaAges Any age - NCT07137416RecruitingPhase 1
Combination drug study for HER2-positive breast and other cancers
This study tests a new combination of two anti-cancer drugs (CX-5461 and T-DXd) for people with HER2-positive breast cancer or other solid tumors. It aims to see if the combination is safe and how well it works.
Boston, MassachusettsAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Little Rock, ArkansasAges 19 years+ - NCT07874490RecruitingPhase 2
Osimertinib plus cyclosporine for advanced lung cancer
This study tests whether adding cyclosporine to the standard drug osimertinib can make it work better in people with advanced non-small cell lung cancer that has a specific EGFR gene change. You can join even if you haven't started treatment or have just started osimertinib within the last 3 weeks.
New York, New YorkAges 18 years+ - NCT04113070Recruiting
Study of childhood weight and early puberty development
This study follows children to see how body weight changes relate to when puberty starts and how it progresses. It may help doctors better understand healthy growth patterns during childhood.
Shanghai, Shanghai MunicipalityAges 6–12 - NCT02808572Recruiting
Blood and urine tests to study heart risk in kidney disease
This study looks for new markers in blood or urine that may help explain heart (cardiovascular) risk in people with chronic kidney disease. It may help doctors better predict risk, especially in those not yet on dialysis.
MontpellierAges 18–95 - NCT04836156RecruitingPhase 1/Phase 2
Personalized pre-surgery treatment for HER2-negative early breast cancer
This study tests a treatment plan chosen using lab drug testing on a patient’s tumor (in a dish). It may help improve outcomes for people with early breast cancer that is HER2-negative by matching therapy to what the tumor seems sensitive to.
BeijingAges 18–75 - NCT02813642Recruiting
Study of heart risk in people starting dialysis
This study looks at heart (cardiovascular) risk factors in people who are just starting dialysis for chronic kidney failure. It may help doctors better understand what heart-related issues to watch for early during dialysis.
Castelnau-le-LezAges 18–90 - NCT05081258Recruiting
Tests presurgery shaping for newborn cleft lip and palate growth
This study looks at whether a presurgery orthodontic shaping method affects how newborns with a cleft lip and palate grow over time. It may help clinicians decide on the best early treatment approach.
Erlangen, BavariaAges 1 day–2 years - NCT04983121RecruitingPhase 2
Neoadjuvant pyrotinib plus ARX788 for HER2-positive breast cancer
This Phase 2 trial studies whether combining pyrotinib with ARX788 given before surgery can work better and be safe in people with HER2-positive breast cancer. It’s designed for tumors that did not respond well enough to earlier trastuzumab and pertuzumab treatment.
Shenyang, LiaoningAges 18–75 - NCT04541095Recruiting
Milk formula for very preterm babies: more vs less beta-palmitate
This study tests an infant milk formula that has a higher or lower amount of beta-palmitate in babies born very early. The goal is to see if the formula supports healthy growth in preterm infants who are stable and can feed through the stomach.
AnconaAges 6 months–7 months - NCT02910180Recruiting
Biobank study of genetic and metabolic data in brain blood vessel disease
This study collects genetic and other health information from people with brain blood vessel (cerebrovascular) problems. It aims to help researchers understand causes and patterns that could lead to better care in the future.
Los Angeles, CaliforniaAges 18 years+ - NCT05991336Recruiting
Growth and development after gene therapy for beta-thalassemia in children
This study looks at how children with transfusion-dependent beta-thalassemia grow and develop after gene therapy. It compares children who have had gene therapy with those who have not, and also with healthy children of the same age and gender.
Tianjin, Tianjin MunicipalityAges 3–14 - NCT05604846Recruiting
Probiotic drops for very preterm babies in Scandinavia
This trial studies whether giving probiotic supplements to extremely preterm newborns helps improve health outcomes. It’s meant for babies born very early, and the results could help guide safer early nutrition and care.
Solna, Stockholm CountyAges 5 months–6 months - NCT06102928Recruiting
Anlotinib plus Aumolertinib for first-line treatment of advanced EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
Kunming, YunnanAges 18 years+ - NCT01873131Recruiting
Laser or timolol gel for fast-growing birthmark in infants
This study compares three approaches—pulsed-dye laser, timolol (a medicated skin solution), or watch-and-wait—to see which works best to slow the growth of a hemangioma birthmark in young babies. It may help find a treatment that shrinks or controls the birthmark as early as possible.
Boston, MassachusettsAges Up to 3 months - NCT07864051Recruiting
Studying blood flow to predict plaque growth in heart arteries
This trial uses special imaging to look at how blood flows through the heart's arteries. It aims to see if certain blood flow patterns can predict where harmful plaque (fatty buildups) may grow, which could help prevent future heart problems.
LondonAges 40 years+ - NCT06192849RecruitingPhase 2
Furmonertinib after surgery for EGFR 20 insertion lung cancer
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
Chengdu, SichuanAges 18 years+ - NCT07869004Enrolling by invitation
Fetuin-B levels in pregnancy with poor fetal growth
This study looks at whether a protein called fetuin-B in the mother's blood is different in pregnancies where the baby is growing slower than expected. It may help doctors understand and manage this condition.
Akçaabat, TrabzonAges 18–45 - NCT03396562Recruiting
Study of early development in babies with extra sex chromosomes
This study follows infants and young children with conditions caused by having an extra sex chromosome (like XXY, XYY, or XXX) to learn how health and development unfold over time. It may help families and doctors understand what to expect and what support could be helpful.
Aurora, ColoradoAges 1 month–1.1 years
Hear when a new Growth trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for growth?
- Yes. Clin2 currently lists 295 recruiting growth studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a growth trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a growth trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.